Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CHS 131

Drug Profile

CHS 131

Alternative Names: AMG 131; INT 131; INT131 besylate; T 0903131; T 131

Latest Information Update: 17 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tularik
  • Developer Coherus BioSciences; InteKrin Therapeutics
  • Class Anti-inflammatories; Antihypercalcaemics; Antihyperglycaemics; Hepatoprotectants; Insulin sensitisers; Neuroprotectants; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; Peroxisome proliferator-activated receptor gamma modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Multiple sclerosis; Type 2 diabetes mellitus
  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 08 Nov 2018 Coherus Biosciences plans a phase II trial for Non-alcoholic steatohepatitis
  • 17 Aug 2018 Preclinical trials in Non-alcoholic steatohepatitis in USA (PO), prior to August 2018
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top